DENVER, Colo., Jun 11, 2024 (247marketnews.com)- Viridian Therapeutics, Inc. (NASDAQ:VRDN) provided details for its plans to initiate a phase 3 clinical trial program for its SC VRDN-003 product candidate for patients with moderate-to-severe TED.
“We are very pleased to have completed a positive Type C meeting with the FDA and to take this next step towards rapidly bringing a highly differentiated treatment option to patients living with TED,” stated Viridian’s President and Chief Executive Officer, Steve Mahoney. “We view VRDN-003 as a potentially best-in-class anti-IGF-1R product candidate that is designed to preserve the compelling IGF-1R clinical response we have seen in our earlier proof-of-concept studies of VRDN-001. We believe this product profile could maximize convenience as a low-volume, infrequent subcutaneous injection and provide better access to treatment for patients.”
Tom Ciulla, Viridian’s Chief Medical Officer, added, “The current standard of care in TED requires 8 intravenous doses, representing a significant burden for patients. Subcutaneous VRDN-003 could transform the treatment experience for patients with TED.”
The post Viridian Therapeutics Provides Subcutaneous VRDN-003 Phase 3 Clinical Program Details appeared first on 24/7 MarketNews.